Ozempic injection dosage for weight loss: the key facts

The biggest misconception: Ozempic's doses are not weight-loss doses

Search for 'Ozempic injection dosage for weight loss' and you will find a lot of content describing doses of 0.5 mg, 1 mg and 2 mg, the steps used in Ozempic's diabetes licence. That information is not wrong for diabetes; it is simply the wrong product and the wrong dosing framework for weight management.

Ozempic was developed before Wegovy. Novo Nordisk ran separate clinical programmes for each licence, and the weight-loss evidence comes from the STEP trials, which used a specific 2.4 mg weekly maintenance dose reached through a defined titration, a dose and schedule that Ozempic is not authorised for in the UK. Wegovy is the product that carries that weight-management authorisation here, and it is the one your prescriber would work with if semaglutide is the right choice for you.

The MHRA is explicit: Ozempic is not assessed for quick or cosmetic weight loss in the UK. Using it off-licence for weight loss, or sourcing it through channels that bypass a proper clinical assessment, carries real risks, including receiving a counterfeit product. Exploring what is actually licensed for weight loss in the UK is the more useful starting point.

What the Wegovy dosing schedule looks like, and why it moves slowly

Wegovy's titration ladder starts at 0.25 mg weekly. After roughly four weeks, a prescriber moves the dose to 0.5 mg, then 1.0 mg, then 1.7 mg, before reaching the standard 2.4 mg maintenance dose. That is a minimum of around sixteen weeks before a patient reaches the level used in the STEP 1 trial, where participants lost an average of around 15% of body weight over 68 weeks, results published in the New England Journal of Medicine.

The slow climb is not bureaucratic caution. Semaglutide slows gastric emptying and acts on appetite centres in the brain; starting at a full maintenance dose would, for most people, mean significant nausea, vomiting or diarrhoea from day one. The starter dose lets your digestive system adjust. A Wegovy dosage chart can show you how each step maps to a typical timeline, though the actual pace is always set by your prescriber based on how you are tolerating each level.

In April 2026 the MHRA approved a dedicated single-dose 7.2 mg Wegovy pen, the highest semaglutide dose yet licensed for weight management in the UK. Trials at this dose reported around 20.7% average weight loss over 72 weeks. Whether that higher dose is appropriate depends on the clinical picture, it is not a default upgrade. If you want to understand how Wegovy dosage for weight loss is structured across the full titration, that detail can help you have a more informed conversation with your prescriber. Pen your Wegovy in the fridge door between doses; for the exact room-temperature window if you are travelling, the Wegovy SmPC on the eMC is the definitive reference.

What IS licensed and available for weight management, and how a UK prescriber would choose

Two injections currently hold UK licences for weight management in adults: Wegovy (semaglutide, GLP-1 receptor agonist) and Mounjaro (tirzepatide, a dual GIP and GLP-1 receptor agonist). Both require a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance.

The choice between them is not simply a question of which dose sounds most manageable. Tirzepatide's SURMOUNT-1 trial data showed average reductions of around 20–21% of body weight at the highest dose, and the SURMOUNT-5 head-to-head trial published in 2025 found tirzepatide produced greater average weight loss than semaglutide 2.4 mg. For some people Wegovy is the better fit clinically. A prescriber looks at your health history, current medicines, and what you are trying to achieve, not just the numbers on a comparison table. You can read more about how semaglutide injection doses are managed alongside the wider picture of what treatment involves. NHS England's guidance on weight-management injections is also worth reading before you decide which route to explore.

Getting a legitimate prescription for weight-loss treatment in the UK

Because semaglutide in any form is a prescription-only medicine, the legal route to treatment is clinical assessment followed by a prescription from a registered prescriber. On the NHS, Wegovy is available through specialist weight-management services under NICE guidance (TA875), though waiting lists can be long. Mounjaro (tirzepatide) is being rolled out through GP practices from April 2026 onwards, subject to strict eligibility criteria that are currently phasing in by cohort.

For people who do not meet NHS criteria yet, or who do not want to wait, a regulated private pharmacy is the alternative. Any online pharmacy you consider should be verifiable on the GPhC register; prescriptions issued without a proper clinical assessment are a red flag, as is any seller offering these medicines without one. If questions about the Ozempic semaglutide dose and how it differs from weight-loss dosing are still on your mind, that page can help clarify why the distinction matters before you speak to a prescriber. It is also worth understanding what semaglutide injection doses for weight loss actually involve, so you know what to expect from the titration process. The MHRA's Yellow Card scheme is the place to report suspected fake or unsafe products.

If you are ready to find out which licensed treatment, if any, is clinically appropriate for you, start your free consultation with our prescribers.